Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Atif J. Khan; Par S. Mehta; Thomas W. Zusag; Philip D. Bonomi; L. Penfield Faber; Susan Shott; Ross A. Abrams

doi:10.1016/j.radonc.2006.09.006

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Atif J. Khan, Par S. Mehta, Thomas W. Zusag, Philip D. Bonomi, L. Penfield Faber, Susan Shott, Ross A. Abrams

Research output: Contribution to journal › Article › peer-review

82 Scopus citations

Abstract

We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

Original language	English (US)
Pages (from-to)	163-167
Number of pages	5
Journal	Radiotherapy and Oncology
Volume	81
Issue number	2
DOIs	https://doi.org/10.1016/j.radonc.2006.09.006
State	Published - Nov 2006
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology
Radiology Nuclear Medicine and imaging

Keywords

Lung cancer
NSCLC
Oligometastases
Oligometastasis

Access to Document

10.1016/j.radonc.2006.09.006

Cite this

@article{e8a02208b3b44b33928a62d6cb87e321,

title = "Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)",

abstract = "We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.",

keywords = "Lung cancer, NSCLC, Oligometastases, Oligometastasis",

author = "Khan, {Atif J.} and Mehta, {Par S.} and Zusag, {Thomas W.} and Bonomi, {Philip D.} and {Penfield Faber}, L. and Susan Shott and Abrams, {Ross A.}",

year = "2006",

month = nov,

doi = "10.1016/j.radonc.2006.09.006",

language = "English (US)",

volume = "81",

pages = "163--167",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

AU - Khan, Atif J.

AU - Mehta, Par S.

AU - Zusag, Thomas W.

AU - Bonomi, Philip D.

AU - Penfield Faber, L.

AU - Shott, Susan

AU - Abrams, Ross A.

PY - 2006/11

Y1 - 2006/11

N2 - We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

AB - We report outcomes on 23 patients with oligometastastic (1 or 2 sites) NSCLC treated with aggressive local, regional, and systemic treatment. The results suggest that this is a favorable subset of patients who may benefit from such an approach, with a 22% rate of long-term survival. This treatment strategy is a departure from the usual practice of palliative-only therapy for all NSCLC patients presenting with metastatic disease.

KW - Lung cancer

KW - NSCLC

KW - Oligometastases

KW - Oligometastasis

UR - http://www.scopus.com/inward/record.url?scp=33751211247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751211247&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2006.09.006

DO - 10.1016/j.radonc.2006.09.006

M3 - Article

C2 - 17050016

AN - SCOPUS:33751211247

SN - 0167-8140

VL - 81

SP - 163

EP - 167

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 2

ER -

Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC)

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this